Characteristic | Univariable | Multivariable | ||
---|---|---|---|---|
β (SE) | p Value | β (SE) | p Value | |
Male gender | −0.63 (0.72) | 0.38 | ||
Age (years) | 0.00 (0.03) | 0.98 | ||
Disease duration (years) | −0.01 (0.04) | 0.71 | ||
Initial patient global | −0.91 (0.15) | <0.01 | −0.12 (0.02) | <0.01 |
BASDAI | −0.38 (0.20) | 0.05 | 0.51 (0.21) | 0.02 |
BASDAI change | 0.19 (0.15) | 0.19 | ||
BASDAI 50% improvement* | 0.23 (0.61) | 0.70 | ||
ASAS 20 response* | −1.49 (0.66) | 0.03 | ||
BASFI | −0.06 (0.17) | 0.73 | ||
BASFI change* | 0.24 (0.15) | 0.12 | ||
BASMI | −0.01 (0.15) | 0.93 | ||
BASMI change* | 0.14 (0.19) | 0.49 | ||
CRP (mg/L) | −0.20 (0.11) | 0.09 | ||
mSASSS | 0.06 (0.18) | 0.75 | ||
Treatment with infliximab† | 0.51 (0.66) | 0.44 |
Analysis performed with linear regression analysis, statistically significant when p≤0.05 (bold).
The gap was calculated as the retrospective patient global minus the initial patient global.
Baseline values of ASSERT were used unless otherwise stated.
*Change scores were calculated between the baselines of ASSERT and EASIC.
†Treatment with infliximab compared with placebo for the first 24 weeks. After 24 weeks all patients were treated with infliximab 5 mg/kg every 6–8 weeks.
ASAS 20 response, more than 20% improvement in Assessment in Ankylosing Spondylitis improvement criteria between the baseline of ASSERT and the baseline of EASIC; ASSERT, Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASDAI 50% improvement, more than 50% change in the BASDAI between the baseline of ASSERT and baseline of EASIC; BASFI, Bath Ankylosing Spondylitis Functional Index; BASMI, Bath Ankylosing Metrology Index; CRP, C reactive protein; mSASSS, modified Stoke Ankylosing Spondylitis Spinal Score; EASIC, European Ankylosing Spondylitis Infliximab Cohort.